There can be a delay in diagnosis of myeloproliferative neoplasms as the symptoms of the diseases can be variable and common, such as fatigue, migraines, and difficulty concentrating, explained Ruben ...
AUSTIN, Texas & MONTREAL--(BUSINESS WIRE)--Forbius, a clinical-stage company that develops biologics for the treatment of cancer and fibrosis, announced today a collaboration agreement with the Icahn ...
Clinical trials offer a unique treatment experience when you live with myeloproliferative disorders. Lower cost of care, direct access to a specialized MDS medical team, and the opportunity to try new ...
JAKis significantly reduce thromboembolic event risk in MPN patients, especially with Jakafi in polycythemia vera and myelofibrosis. A meta-analysis of 23 studies showed a 48% reduction in ...
The NCCN Guidelines for MPNs have seen frequent updates recently, reflecting new therapeutic approvals and options for patients. Emphasis on clinical trials as preferred treatment options highlights ...
Atavistik Bio is led by an experienced team of drug hunters with a proven track record of developing marketed small molecule therapies and supported by top-tier investors, including The Column Group, ...
We present a review of critical concepts and produce recommendations on the management of Philadelphia-negative classical myeloproliferative neoplasms, including monitoring, response definition, first ...
The author(s) indicated no potential conflicts of interest. If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select ...
SAN DIEGO — First-line treatment with ruxolitinib led to “clinically meaningful” positive results versus best available therapy in patients with high-risk polycythemia vera, according to data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback